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INTRODUCTION
Recurrence is the most common complication of pterygium 
sur gery and a cause of patient discontent; these are primary chal-
lenges for this surgery(1). Many approaches, including beta therapy, 
antimetabolic agents, and subconjunctival bevacizumab, have been 
proposed to prevent recurrence. However, these treatments are often 
associated with complications(2-6).
Tranilast inhibits the growth of pterygium-derived cells(7); the-
refore, its use may reduce the recurrence of pterygium. Tranilast, 
N-[3,4-dimethoxycinnamonyl]-anthranilic acid, is an antiallergy drug 
that was first used to prevent bronchial asthma and allergic rhinitis. 
ABSTRACT
Purpose: To determine the efficacy of tranilast as an adjunctive therapy in con-
junctival autograft. 
Methods: Twenty-nine patients were randomly allocated to the Tranilast Group 
(n=15) or the Control Group (n=14). The Tranilast Group received a subconjuncti-
val injection of 0.5% tranilast 30 days prior to surgery. Conjunctival autograft 
was performed in both groups using fibrin sealant and 0.02% subconjunctival 
mitomycin C at the end of the surgery. After the resection of the pterygium, 
immunohistochemistry was performed with 100 cells to identify epithelial cells 
positive for transforming growth factor-β (TGF-β). Subjective symptoms were 
evaluated using a 5-point scale, and the recurrence rate was assessed. 
Results: Both groups showed improvements in their symptoms and similar clinical 
results. Compared with the Control Group, the Tranilast Group failed to show a de-
creased recurrence rate (p=0.59). However, the number of epithelial cells expressing 
TGF-β was lower in the Tranilast Group (5 cells; 95% CI: 2.56-13.15; Control Group, 16 
cells, 95% CI: 11.53-24.76; p=0.01). Minimal but reversible complications, including 
glaucoma secondary to corticosteroids and granuloma, occurred during the study. 
Conclusion: Tranilast was effective in decreasing the number of pterygium epi-
thelial cells expressing TGF-β. 
Keywords: Transforming growth factor beta 1; Pterygium/therapy; Recurrence; 
Au to grafts; Anti-allergic agents/therapeutic use; Transplantation, autologous; Con-
junctiva/surgery
RESUMO
Objetivo: Determinar a eficácia do tranilast, como terapia auxiliar no transplante 
autólogo de conjuntiva. 
Métodos: Vinte e nove pacientes foram randomizados em dois grupos: Grupo Tratado 
(15) e Grupo Controle (14). Trinta dias antes da cirurgia, o Grupo Tratado recebeu uma 
injeção subconjuntival de tranilast a 0,5%. O transplante autólogo de conjuntiva foi 
realizado em ambos os grupos, usando-se a cola de fibrina e a mitomicina 0,02% 
subconjuntival, ao final da cirurgia. Cada paciente foi examinado por 12 meses de acom-
panhamento. A imuno-histoquímica foi realizada, mediante um total de 100 células, 
a fim de que se contassem as células epiteliais positivas, para o fator de crescimento 
transformador beta (TGF-β), após a cirurgia do pterígio. Os sintomas subjetivos foram 
avaliados usando-se uma escala de cinco pontos, e a taxa de recorrência foi avaliada. 
Resultados: Os 2 grupos apresentaram melhora dos sintomas e com resultados 
clínicos similares. Quando comparado com o Grupo Controle, o Grupo Tratado falhou 
em mostrar uma diminuição da taxa de recorrência (p=0,59). Entretanto o número 
de células epiteliais expressando o TGF-β foi menor no Grupo Tratado (5 células; 95% 
CI=2,56-13,15; Grupo Controle, 16 células; 95% CI: 11,53-24,76, p=0,01). Complicações 
mínimas, mas reversíveis, ocorreram durante o estudo, incluindo glaucoma secundário 
ao uso de corticoide e granuloma. 
Conclusão: O tranilast foi efetivo em diminuir o número células epiteliais do pterígio 
expressando o TGF-β. 
Descritores: Fator de crescimento transformador beta 1; Pterígio/terapia; Recidiva; Autoen-
xertos; Antialérgicos/uso terapêutico; Transplante autólogo; Túnica conjuntiva/cirurgia
Recent studies have shown that tranilast has an antifibrotic effect, 
inhibiting the proliferation of fibroblasts and their subsequent trans-
formation into myofibroblasts(8). Furthermore, tranilast has been asso-
ciated with decreases in posterior capsule opacification after cataract 
surgery and inhibition of scaring after glaucoma filtering surgery(9,10).
The present study aimed to determine the efficacy of tranilast 
for preventing pterygium recurrence. In addition, this study aimed 
to evaluate the symptoms and presence of transforming growth 
factor-β (TGF-β) in excised tissues when 0.5% tranilast was adminis-
tered via subconjunctival injection prior to surgery as adjunctive the-
rapy in conjunctival autograft (CAU) for cases of primary pterygium.
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METHODS
This prospective, randomized control trial included 50 patients 
who underwent primary pterygium treatment at the Hospital de 
Base (HB) of the Medical School in São José do Rio Preto between 
June and December 2010.
The inclusion criteria were pterygium with a horizontal length 
of >2 mm measured from the anatomic limbus and subjective eye 
symptoms (irritation, burning, excessive tearing, dry eye sensation, 
foreign body sensation, and hyperemia). The exclusion criteria were 
a lack of connective tissue, history of eye trauma, glaucoma, dysfunc-
tional tear syndrome, rosacea, neurotrophic keratopathy, systemic or 
topical use of immunosuppressive drugs, age <18 years, and vulnera-
bility related to physical or mental illness.
Pterygium was categorized according to the classification des -
cribed by Tan et al.(11). Patients were randomly allocated into 2 equal 
groups that included a Control Group (CG) treated with CAU em-
ploying fibrin glue (Tissucol®; Baxter AG, US) and a Tranilast Group 
(TG) treated with a 0.1-mL subconjunctival injection of tranilast 
solution (1.0 mg/mL). The subconjunctival injection was placed in 
the head of the pterygium as adjunctive therapy 30 days before CAU 
employing fibrin sealant (Tissucol®; Baxter AG). Tobramycin eye drops 
(0.3%, Tobrex®; Alcon Laboratories, Fort Worth, TX, USA) were admi-
nistered 4 times daily for 3 days after the injection. Randomization 
was performed by means of a table of random numbers.
A single surgeon (GCAJ) who was masked to the patients’ group 
assignments performed all the surgeries. Surgical procedures were 
performed in an operating room using an ophthalmic microscope 
after instillation of 1.0% tetracaine chlorhydrate (every 5 min over 30 
min and in the perioperative period if necessary). CAU was performed 
following the technique of Koranyi et al.(12) with some modifications 
to cover the bare regions of the sclera. Mitomycin C (0.1 mL of 0.02%) 
was injected postoperatively into the remaining conjunctiva above 
and below the site where CAU was placed and with extreme care to 
prevent wetting of the ocular surface. Tobramycin-dexamethasone 
ointment (TobraDex®; Alcon Laboratories) was applied, and the eye 
was occluded using a bandage, which the patient was instructed to 
remove the following morning. Tobramycin eye drops (0.3%, Tobrex®; 
Alcon Laboratories) were prescribed 4 times daily for 7 days and 
dexamethasone drops (0.1%, Maxidex®; Alcon Laboratories) were 
prescribed every 3 h during the first week and then 4 times daily for 
the following 3 weeks.
The excised pterygium was stored in liquid nitrogen. After all 
the patients had been treated, 7 samples from each group were ran-
domly selected for analysis. Immunohistochemistry was performed 
in the surgical pathology service of the HB. The pterygium tissue sam-
ples were submitted to serial 6-µm thick sectioning with a cryostat 
at -20°C. Histological preparations were performed on slides covered 
with polylysine that was fixed in cold acetone for 15 min and washed 
with phosphate-buffered solution (PBS) 3 times for 5 min. The slides 
were then treated with 0.5 peroxidase (composition: 49.17 mL 
PBS, 49.17 mL methanol, and 16.5 mL H
2
O
2
) for 10 min to block 
endogenous peroxidase and were incubated in horse serum for 30 
min at room temperature to prevent non-specific binding. TGFβ1/2 
primary antibody (sc-80346; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) diluted at 1/20 in bovine albumin was used for about 12 h 
at 4°C. Thereafter, the slides were washed 3 times for 5 min in PBS. 
The slides were then incubated in a secondary antibody (biotinyla-
ted anti-mouse antibody; ABC Staining System, sc-2017; Santa Cruz 
Biotechnology) for 30 min and washed in PBS. The next step was 
to incubate with the ABC reagent for 30 min. Next, the slides were 
incubated in 0.05% 3’, 5’-diaminobenzidine (Sigma-Aldrich Co LLC, 
St Louis, USA), contra-stained using Harris hematoxylin, and washed. 
The negative control comprised exposure to the secondary antibody 
and the ABC reagent, without exposure to the primary antibody. Pig 
gut was used for the positive control. An experienced pathologist 
(DDN) blinded to the group assignments evaluated the immunohis-
tochemical slides using an optical microscope at 400´ magnification 
in a field-oriented assessment of the epithelial region of the ptery-
gium. Cells with either total or partial staining of the circumference of 
the epithelial cytoplasmic membrane were considered positive and 
those that remained unstained were considered negative. The results 
were based on 100 cells obtained from each sample.
Components of the tranilast solution were acquired from Cayman 
Chemicals (Catalog 13044; Ann Arbor, MI, USA) and manufactured by 
Ophthalmos (Sao Paulo, Brazil). The preparations were labeled (0.2 mL 
of 5 mg/mL tranilast) and stored at -20°C. 
A graft was considered a success when it remained intact after 
surgery without recurrence. Recurrence was defined on the basis of 
the description provided by Sebban and Hirst(13). Subjective symptoms 
of burning, irritation, excessive tearing, hyperemia, foreign body 
sensation, and dry eye sensation were assessed prior to surgery on the 
7th postoperative day and during the 1st, 3rd, 6th, and 12th postoperative 
months. The symptoms were quantified using the following 5-point 
abnormal sensation scale adapted from Lim-Bon-Siong et al.(14): 0) 
none; 1) somewhat bothersome but tolerated; 2) quite bothersome; 
3) very bothersome; and 4) extremely bothersome. A non-medical 
professional who did not participate in the surgery conducted the 
interviews to avoid investigator bias. Another ophthalmologist (LA) 
performed the ophthalmic evaluations under a slit lamp over the 
12 months of the study to assess the integrity of the graft, possible 
complications, and the recurrence rate.
Fischer’s exact test was used to evaluate the recurrence rate at 
the end of the 12 month study. The Mann-Whitney U test was used 
to evaluate the positivity of epithelial cells with respect to TGF-β and 
to compare the symptoms between groups at each time interval. 
The Friedman test was used to analyze the symptoms evaluated 
within groups using the 5-point scale. Graph Pad Prism 5 (Graph Pad 
Software Inc., La Jolla, CA, USA) was used for statistical analysis and 
to build graphs. The significance level was set at 0.05.
All participants signed consent forms. The study protocol was 
approved by the Ethics Committee of FAMERP (#30492009) and 
was registered as a clinical trial with the U.S. National Institutes of 
Health (#NCT01003613). The authors certify that the protocol for 
the research project conformed to the provisions of the Declara-
tion of Helsinki of 1995 (as revised in Edinburgh 2000) and declare 
no financial support or relationships that may pose a conflict of 
interest.
RESULTS
In total, 29 patients with primary pterygium were included in 
the study; 15 were assigned to TG and 14 were assigned to CG. A 
CONSORT-based diagram showing patient flow through each step 
of the trial is shown in figure 1.
The patients completed at least 12 months of follow-up. All 
pterygia were primary and located in the nasal region. As the data 
presented in table 1 indicate, both groups were similar at baseline 
in terms of gender, laterality, age, horizontal size, vertical size, ptery-
gium classification, and length. All variables were statistically similar 
between the groups.
Some degree of edema that was present in each graft after sur-
gery improved with time. One patient lost a graft during the study 
and was therefore excluded. Three patients who presented with 
elevated eye pressure were also excluded from the study. Thirteen pa-
tients were lost to follow-up, 3 evolved with granuloma that required 
extended treatment with corticosteroids, and 1 died of myocardial 
infarction. Thus, 21 patients were lost to follow-up and 29 patients 
completed the study. 
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Both groups used 0.1 mL mitomycin C (0.2 mg/mL) in the sub-
tenonian region near the upper and lower conjunctive areas of the 
donor conjunctiva, and there were no complications during the first 
12 months. Recurrence occurred in 2 CG patients and 1 TG patient 
after a year (p=0.59). The TG patient and 1 CG patient presented with 
small (0.5 mm) fibrovascular invasions in the limbal region. The other 
CG patient was diagnosed with conjunctival recurrence.
None of the patients presented with symblepharon. Both groups 
showed significant improvement in subjective symptoms at the end 
of the 12-month follow-up period, but there were no significant 
differences in the 6 subjective symptoms between the 2 groups 
(Figures 2 and 3).
The percentage of cells expressing TGF-β in TG (mean: 7.85%; 
range: 2.56-13.15%) was lower than that in CG (mean: 18.14%; range: 
11.53-24.56%, p=0.01; Figure 4). Figure 5 shows how calculations 
for the expressed TGF-β cells were performed using images from a 
patient in CG. The esthetic results were very similar between the 2 
groups (Figure 6).
DISCUSSION
The recurrence rates in this study, 6.66% for TG and 14.28% for 
CG, were similar to other reports using different preoperative and in-
traoperative regimens with adjuvant mitomycin C. Recurrence rates of 
4.54% and 5.4% have been reported in 2 separate studies(15,16). Another 
study reported a recurrence rate of 15% after 4 years of follow-up(17).
 The mean age of the patients in this study was 46.43 years for CG 
and 44.73 for TG. The difference in mean age may explain the higher 
recurrence rate in our study compared with the patients treated in 
another study who had a mean age of 60 years(15) because the recur-
rence rate of pterygium is higher in younger individuals(18).
In a previous study, the 4-year recurrence rate of CAU alone was 
shown to be 15%, whereas the recurrence rate after the application 
of mitomycin C on bare sclera alone was 38%(17). In the current study, 
CAU was combined with mitomycin C in an attempt to combine and 
enhance the effects of each treatment.
However, it is important to note that the number of samples in 
each group was too small to determine the efficacy of tranilast. Fur-
thermore, the loss to follow-up was very high (Figure 1), and the po-
wer of the study for the variable recurrence was approximately 50%. 
Anduze(19) also examined the effect of 0.1 mL of mitomycin C 
(0.2-0.4 mg/mL) applied directly under the conjunctival flaps posto-
peratively using a similar procedure to that used in the current study. 
Table 1. Preoperative characteristics of the 2 groups of patients who completed the study
Control group Tranilast group p-value
n 14 15
Gender (male/female) 8/6 5/10
Laterality (right/Left) 9:5 9:6 
Age (years) 46.43 ± 13.12 (38.85-54.01) 44.73 ± 12.16 (38-51.47) 0.74
Horizontal length (mm) 3.82 (3.14-4.49) 3.30 (2.87-3.72) 0.25
Vertical length (mm) 5.30 (4.5-6.09) 4.80 (4.22-5.37) 0.22
Pterygium Tan Grading
T1 atrophic 0 (0%) 0 (0%)
T2 intermediate 3 (21.43%) 2 (13.33%)
T3 fleshy 11 (78.57%) 13 (86.67%)
Time (months) 12.71 (12.24-13.19) 12.93 (12.49-13.38) 0.45
Pterygium Tan Grading(11): Grade 1 (atrophic) - episcleral vessels under the body of the pterygium are clearly observed; Grade 3 (trophic) - episcleral vessels under the body of the pterygium 
are entirely obscured; and Grade 2 (intermediate) - types of pterygium that do not fit into 1 of the 2 categories described above.
Figure 1. Flow diagram for the included patients during each step of the study.
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The mechanism of action of tranilast differs from that of mi-
tomycin C. Tranilast is safe to use even when the 2 agents are used 
concurrently, as observed in the present study. Tranilast can inhibit 
the proliferation and chemotaxis of pterygium-derived fibroblasts(7), 
as well as collagen synthesis of keloid fibroblasts(21).
There were some concerns in the present study regarding the 
toxicity of mitomycin, especially for late postoperative complications. 
However, no complications associated with its use were observed. 
One patient in CG lost the graft during the early postoperative period, 
which was possibly due to scratching of the eye. Other complications 
were granuloma formation and increased eye pressure secondary to 
corticosteroids.
One case report, in which tranilast ophthalmic solution was used, 
reported its effectiveness in preventing pterygium recurrence and 
inhibiting symblepharon and granulomas without adverse reac-
tions(22). However, few studies reported in the literature have assessed 
both the preoperative and postoperative symptoms associated with 
pterygium surgery. In the present study, there were no significant 
differences in the symptoms between the groups and the symptoms 
typically disappeared 30 days postoperatively (Figures 2 and 3).
TGF-β, which is present in the epithelial cells, stromal cells, vas-
cular endothelial cells, and vascular basal membrane of pterygium 
tissue, is a multifunctional protein that regulates cell migration, 
proliferation, differentiation, and apoptosis of many cell types(23). In 
the normal conjunctiva, positive immunolabeling for TGF-β is much 
weaker than in pterygium tissue(24). The present study demonstrated 
moderate expression of TGF-β in pterygium epithelial cells in CG 
compared with expression in TG (Figure 4).
Although a previous study found that an increase in TGF-β levels 
in the pterygium was comparable with that in normal conjunctiva(25), 
the immunohistochemical analysis reported here was similar to the 
findings of that study, showing that TGF-β was mainly expressed 
in the pterygium epithelial cells (Figure 5). The numbers of stained 
epithelial cells were significantly different between the 2 groups 
(p=0.01; Figure 4). Therefore, tranilast inhibits the secretion of TGF-β1 
from conjunctival cells(26).
To the best of our knowledge, this study is the first to report sub-
conjunctival injection of tranilast 30 days prior to pterygium surgery. 
Tsuji et al.(22) described other options, that include similar administra-
tion such as the administration of mitomycin C in the postoperative 
period, that may be viable.
Based on the above findings, we consider that tranilast ophthal-
mic solution administered by conjunctival injection before pterygium 
surgery may effectively decrease TGF-β in epithelial pterygium tissue. 
In contrast, we routinely use topical steroids and topical antibiotics 
after most eye surgeries. Therefore, we cannot ignore the possibility 
that steroids affected the postoperative outcome because they also 
have strong anti-inflammatory effects, and theoretically, could reduce 
recurrence after pterygium excision. However, pterygium recurrence 
Figure 2. Subjective symptoms before and after surgery in patients in the tranilast 
group (TG).
Figure 3. Subjective symptoms before and after surgery in patients in the control 
group (CG).
Figure 4. Expression of TGF-β in the epithelial cells of the pterygium in the control group 
(CG) compared with the tranilast group (TG).
Rubinfeld et al.(6) described 10 cases with severe complications 
that were associated with mitomycin C use after pterygium surgery. 
The safe dosage of mitomycin C is lower than 0.3 mg/mL(20), and it 
appears that the drug’s effective concentration overlaps with the 
concentration capable of causing adverse reactions.
Figure 5. A) Positive immunohistochemical staining for TGF-β in the cytoplasmic 
membrane (arrows), with predominance in the superficial and middle portions of the 
conjunctival epithelium of the pterygium. The basal portion of the epithelium is scar-
cely marked [frozen slides with focal artifacts (star). Magnification: 400×]. B) Negative 
immunohistochemical staining for TGF-β. The cytoplasmic membrane was not stained. 
[frozen slides. Magnification: 400×].
A B
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often occurs with topical steroids, suggesting that their an ti-in -
flammatory effect is insufficient to prevent recurrence completely.
This study has some limitations, including the absence of a con-
trol injection of the tranilast vehicle. TGF-β may interact directly or 
indirectly during the pathogenesis of pterygium, though this remains 
to be proven(24).
Subconjunctival tranilast was effective in decreasing the expression 
of TGF-β in pterygium epithelial cells.
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(E) 6 months after surgery, and (F) 12 months after surgery.
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